# Molecular Tumorigenesis of Bladder Cancer

> **NIH NIH P01** · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · 2022 · $1,338,589

## Abstract

Overall: Project Summary
Of the most prevalent cancers in the United States over the last three decades, bladder cancer (BC) has
consistently ranked the fifth in annual incidence and the first in medical expenses on a per-case basis. Despite
its high prevalence and staggering medical costs, BC is until recently among the least studied cancers with
limited efforts in basic, translational and clinical research. Consequently, few assays and biomarkers exist to
reliably diagnose BC and predict its progression and few new therapeutic approaches are available to
effectively manage BC. Compounding this is the fact that BC is highly heterogeneous comprised of major
phenotypic variants and molecular subtypes, as evidenced by previous genetic studies and recent whole-
genome/-exome/transcriptome analyses. Over the last five years, the investigators of our PO1 Team have
worked together in a highly synergistic and collaborative manner in tackling the biological bases of BC
heterogeneity and made significant strides in: discerning the combinatorial genetic drivers of major BC
variants; establishing DNA damage and repair as distinguishing features of different types of BC; establishing
XIAP as a critical driver of BC invasion; and identifying urothelial subpopulations as potential progenitor cells of
BC variants. This renewal application builds on this forward momentum and focuses on a much deeper and
expanded scientific theme – the genetic, carcinogenomic, molecular and cellular underpinnings of BC
heterogeneity, by asking several important new questions. What dictates the origin(s) of major BC variants:
divergent genetic drivers versus divergent progenitor cells (Project 1; P1)? Do the nitrosamines converted from
nicotine in E-cigarette vapor within host cells cause muscle-invasive BC and how do they affect urothelial DNA
damage and repair (P2)? And is there a master switch that drives the formation of basal-subtype muscle-
invasive BC (P3)? Results from this highly coordinated, collaborative team effort should contribute to the major
leap forward in our understanding of the biological bases of BC heterogeneity, leading to the development of
novel biomarkers and therapeutics for this highly prevalent but extremely under-studied disease.

## Key facts

- **NIH application ID:** 10455728
- **Project number:** 5P01CA165980-09
- **Recipient organization:** NEW YORK UNIVERSITY SCHOOL OF MEDICINE
- **Principal Investigator:** XUE-RU WU
- **Activity code:** P01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $1,338,589
- **Award type:** 5
- **Project period:** 2013-09-12 → 2024-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10455728

## Citation

> US National Institutes of Health, RePORTER application 10455728, Molecular Tumorigenesis of Bladder Cancer (5P01CA165980-09). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10455728. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*